Eloxx Pharmaceuticals Reports $4.5 Million Net Loss and $62 Million Cash Position for Q2 2026

Eloxx Pharmaceuticals, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of $4.5 million for the second quarter, compared to a loss of $1.9 million in the same period last year, marking an increase of 138%. For the first half of 2026, the net loss was $8.3 million, up from $3.6 million in the prior year. Operating expenses surged to $4.5 million for the quarter, a 181% increase from $1.6 million in Q2 2025, driven primarily by heightened research and development costs associated with clinical trials and increased administrative expenses.

Eloxx's financial position improved markedly, with cash and cash equivalents rising to $62.0 million as of June 30, 2026, compared to $4.8 million at the end of 2025. This increase was largely due to a successful public offering in June 2026, which generated net proceeds of $58.3 million. The company also completed a reverse stock split in May 2026, reducing its authorized shares from 500 million to 100 million, which was part of its strategy to enhance its stock price and comply with Nasdaq listing requirements.

Operationally, Eloxx is focused on advancing its lead product candidate, exaluren, which is in clinical development for treating rare kidney diseases. The company received clearance to initiate a Phase 2b clinical trial for exaluren in patients with nonsense mutations associated with autosomal recessive Alport Syndrome, expected to start in the third quarter of 2026. Additionally, Eloxx has licensed its product candidate ZKN-013 to Almirall, S.A., which is developing it for rare skin diseases. The company remains eligible for up to $470 million in milestone payments and royalties from this collaboration.

The filing also highlighted the company's ongoing challenges, including a history of operating losses and the need for substantial additional funding to support its operations. Eloxx anticipates continued net losses and negative cash flows for the foreseeable future, emphasizing the importance of achieving regulatory approvals and commercializing its product candidates to transition to profitability. The company is actively working to strengthen its internal controls and financial reporting processes, addressing a material weakness identified in its financial reporting controls.

Looking ahead, Eloxx believes its current cash reserves will sustain its operations for at least the next twelve months. The company is committed to advancing its clinical programs and exploring additional funding opportunities to support its growth and development objectives.